Skip to main content
CStone Pharmaceuticals logo

CStone Pharmaceuticals — Investor Relations & Filings

Ticker · 2616 ISIN · KYG2588M1006 LEI · 300300095A57F80T2461 HKEX Manufacturing
Open in API
Filings indexed 3,371 across all filing types
Latest filing 2025-03-26 Regulatory Filings
Country KY Cayman Islands
Listing HKEX 2616

About CStone Pharmaceuticals

http://www.cstonepharma.com

CStone Pharmaceuticals is an innovation-driven biopharmaceutical company focused on the research, development, and commercialization of anti-tumor drugs. The company is dedicated to addressing the unmet medical needs of cancer patients globally. Its core therapeutic focus is on innovative immuno-oncology and molecularly targeted therapies. The R&D pipeline is strategically balanced, featuring potential first-in-class or best-in-class assets, including Antibody-Drug Conjugates (ADC) and multi-specific antibodies. CStone has successfully launched four innovative drugs and secured multiple New Drug Application and indication approvals.

Recent filings

Filing Released Lang Actions
VOLUNTARY ANNOUNCEMENT - CSTONE TO SHOWCASE FIVE LATEST RESEARCH ACHIEVEMENTS AT AACR 2025
Regulatory Filings Classification · 1% confidence The document is a voluntary announcement filed on the HKEX platform by CStone Pharmaceuticals regarding its plans to showcase research achievements at a scientific conference (AACR 2025). It contains no financial results, no board changes, no dividends, no share issues, no management discussion of earnings, no audit opinions, no M&A activity, and no other narrowly defined filing type applies. Therefore it is best classified under the fallback category for general regulatory announcements.
2025-03-26 English
NOTICE OF 2024 ANNUAL RESULTS PRESENTATION
Report Publication Announcement Classification · 1% confidence The document is not the full Annual Report nor the financial results themselves; it is a formal announcement under HKEx rules notifying investors of the date, time, and format for the forthcoming 2024 annual results publication and presentation. It does not contain the report content but announces when and where it will be published and how investors can participate. This aligns with the definition of a Report Publication Announcement (RPA).
2025-03-25 English
VOLUNTARY ANNOUNCEMENT - CSTONE SUBMITS APPLICATION TO THE EUROPEAN MEDICINES AGENCY FOR NEW INDICATION OF SUGEMALIMAB IN STAGE III NON-SMALL CELL LUNG CANCER
Regulatory Filings Classification · 1% confidence The document is a corporate voluntary announcement by CStone Pharmaceuticals regarding the submission of a regulatory application to the European Medicines Agency for a new drug indication. It is not a financial report, earnings release, board management change, dividend notice, or other specified category. It is a general regulatory announcement about company operations, fitting the fallback category “Regulatory Filings” (RNS).
2025-03-24 English
DATE OF BOARD MEETING
Report Publication Announcement Classification · 1% confidence The document is a short announcement (1,395 characters) on the Hong Kong Exchange’s platform notifying investors of a board meeting date to consider and approve the annual results for the year ended December 31, 2024, and to publish them. It does not contain the results themselves but merely schedules the publication. Under the ‘MENU VS MEAL’ rule, this is an announcement about the timing/release of a report, not the report itself. Therefore it fits the Report Publication Announcement (RPA) category.
2025-03-17 English
NOTICE OF BOARD MEETING
Regulatory Filings Classification · 1% confidence The document is a “Notice of Board Meeting” announcing the date and agenda (considering audited annual results and dividend) rather than presenting the actual financial results or changing board composition. It is an announcement of a meeting and not an AGM information pack, not a full report, not a management change, nor a dividend declaration. Under our taxonomy it does not fit the specific categories, so it falls into the general Regulatory Filings (RNS) category.
2025-03-13 English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 28 FEBRUARY 2025
Regulatory Filings Classification · 1% confidence The document is a monthly listing rule return (Form FF301) filed with the Hong Kong Exchange under Chapter 19B, detailing movements in share capital, issued shares, share options, etc. It is a regulatory compliance submission rather than an annual report, earnings release, management change, or specific transaction notice. It therefore falls into the fallback “Regulatory Filings” category (RNS).
2025-03-06 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.